EyeGate Pharmaceuticals, Inc. – NASDAQ:EYEG

EyeGate Pharmaceuticals stock price today

$35.685
+0.23
+0.66%
Financial Health
0
1
2
3
4
5
6
7
8
9

EyeGate Pharmaceuticals stock price monthly change

-1.17%
month

EyeGate Pharmaceuticals stock price quarterly change

-1.17%
quarter

EyeGate Pharmaceuticals stock price yearly change

-1.38%
year

EyeGate Pharmaceuticals key metrics

Market Cap
25.34M
Enterprise value
19.87M
P/E
-26.51
EV/Sales
993.85
EV/EBITDA
-3.23
Price/Sales
1272.07
Price/Book
4.97
PEG ratio
-2.54
EPS
-1.67
Revenue
N/A
EBITDA
-10.38M
Income
-10.43M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-28174.86%
Oper. margin
-30735.62%
Gross margin
100%
EBIT margin
-30735.62%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

EyeGate Pharmaceuticals stock price history

EyeGate Pharmaceuticals stock forecast

EyeGate Pharmaceuticals financial statements

EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG): Profit margin
Dec 2020 12.05K -2.41M -20032.88%
Mar 2021 0 -2.58M
Jun 2021 0 -2.46M
Sep 2021 0 -2.96M
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG): Earnings per share (EPS)
2021-03-25 -0.44 -0.52
2021-05-12 -0.38 -0.37
2021-08-12 -0.42 -0.35
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG): Debt to assets
Dec 2020 15157559 8.15M 53.82%
Mar 2021 20620602 7.93M 38.48%
Jun 2021 18100060 7.64M 42.24%
Sep 2021 25493339 8.14M 31.95%
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG): Cash Flow
Dec 2020 -1.70M -244.43K 218K
Mar 2021 -2.57M -58.11K 8.03M
Jun 2021 -2.63M -5.74K -278.19K
Sep 2021 -2.27M 0 9.75M

EyeGate Pharmaceuticals alternative data

EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG): Employee count
Aug 2023 14
Sep 2023 14
Oct 2023 14
Nov 2023 14
Dec 2023 14
Jan 2024 14
Feb 2024 14
Mar 2024 14
Apr 2024 14
May 2024 14
Jun 2024 14
Jul 2024 14

EyeGate Pharmaceuticals other data

EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG): Insider trades (number of shares)
Period Buy Sel
Jan 2021 3062202 0
Jul 2021 0 3221326
Aug 2021 0 192775
Nov 2021 17853 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
STREM BRIAN M. director, officer: President an..
Common Stock 17,853 $1.41 $25,173
Sale
ARMISTICE CAPITAL, LLC director, 10 percent owner
Common Stock 192,775 $2.4 $463,046
Sale
ARMISTICE CAPITAL, LLC director, 10 percent owner
Common Stock 68,188 $2.69 $183,562
Sale
ARMISTICE CAPITAL, LLC director, 10 percent owner
Common Stock 400,000 $3 $1,200,000
Sale
ARMISTICE CAPITAL, LLC director, 10 percent owner
Common Stock 375,443 $3.28 $1,232,579
Sale
ARMISTICE CAPITAL, LLC director, 10 percent owner
Common Stock 2,377,695 $5.47 $13,001,236
Purchase
ARMISTICE CAPITAL, LLC director, 10 percent owner
Common Stock 1,531,101 $5.23 $8,000,003
Purchase
ARMISTICE CAPITAL, LLC director, 10 percent owner
Warrants 1,531,101 N/A N/A
Purchase
ARMISTICE CAPITAL, LLC director, 10 percent owner
Common Stock 0 N/A N/A
Purchase
ARMISTICE CAPITAL, LLC director, 10 percent owner
Common Stock 11,000 $6.18 $67,980
Patent
Application
Filling date: 23 Mar 2021 Issue date: 30 Sep 2021
Application
Filling date: 22 Mar 2021 Issue date: 23 Sep 2021
Application
Filling date: 30 Apr 2020 Issue date: 5 Nov 2020
  • What's the price of EyeGate Pharmaceuticals stock today?

    One share of EyeGate Pharmaceuticals stock can currently be purchased for approximately $35.69.

  • When is EyeGate Pharmaceuticals's next earnings date?

    Unfortunately, EyeGate Pharmaceuticals's (EYEG) next earnings date is currently unknown.

  • Does EyeGate Pharmaceuticals pay dividends?

    Yes, EyeGate Pharmaceuticals pays dividends and its trailing 12-month yield is 4.67% with 0% payout ratio. The last EyeGate Pharmaceuticals stock dividend of undefined was paid on 6 Sep 2025.

  • How much money does EyeGate Pharmaceuticals make?

    EyeGate Pharmaceuticals has a market capitalization of 25.34M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 99.55% to 12.06K US dollars. EyeGate Pharmaceuticals made a loss 8.09M US dollars in net income (profit) last year or -$0.35 on an earnings per share basis.

  • What is EyeGate Pharmaceuticals's stock symbol?

    EyeGate Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "EYEG".

  • What is EyeGate Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of EyeGate Pharmaceuticals?

    Shares of EyeGate Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does EyeGate Pharmaceuticals have?

    As Jul 2024, EyeGate Pharmaceuticals employs 14 workers.

  • When EyeGate Pharmaceuticals went public?

    EyeGate Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 13 Feb 2015.

  • What is EyeGate Pharmaceuticals's official website?

    The official website for EyeGate Pharmaceuticals is eyegatepharma.com.

  • Where are EyeGate Pharmaceuticals's headquarters?

    EyeGate Pharmaceuticals is headquartered at 271 Waverley Oaks Rd Ste 108, Waltham, MASSACHUSETTS.

  • How can i contact EyeGate Pharmaceuticals?

    EyeGate Pharmaceuticals's mailing address is 271 Waverley Oaks Rd Ste 108, Waltham, MASSACHUSETTS and company can be reached via phone at +1 781 788 9043.

EyeGate Pharmaceuticals company profile:

EyeGate Pharmaceuticals, Inc.

eyegatepharma.com
Exchange:

NASDAQ

Full time employees:

14

Industry:

Biotechnology

Sector:

Healthcare

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

271 Waverley Oaks Rd Ste 108
Waltham, MASSACHUSETTS 02452

CIK: 0001372514
ISIN: US30233M5031
CUSIP: 30233M503